New scan could match breast cancer patients to best therapy
NCT ID NCT06830382
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a special PET scan that uses a radioactive tracer to detect HER2 protein on cancer cells. The goal is to see if this scan can better identify which patients with metastatic breast cancer will benefit from a targeted drug called T-DXd. About 70 women with advanced breast cancer will receive the scan and then treatment, and researchers will compare scan results to how well the tumor responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive tracer called [68Ga]Ga-ABY-025 used in PET scans
What this could lead to
If successful, this imaging method could help doctors choose the right treatment for each patient, improving outcomes and reducing unnecessary side effects.
What could go wrong
This is an early exploratory study with only 70 participants. The scan may not reliably predict treatment response, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University hospital
RECRUITINGSolna, 17176, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••